

**AMENDMENTS TO THE SPECIFICATION**

**In the Title:**

*Please replace the Title of record with the title below:*

METHODS OF AFFECTING FEEDING AND WEIGHT IN MAMMALS BY  
ADMINISTRATION OF RELAXIN-3

**In the Abstract:**

*Please replace the Abstract of record with the attached substitute Abstract (clean copy).*

*The changes made to the Abstract are shown below:*

**ABSTRACT**

~~The present inventors have found that relaxin-3 has a~~Relaxin-3 is found to have feeding-stimulating activity, a-body weight increasing activity, and fat weight increasing activity when ~~by intracerebroventricularly administering relaxin-3~~administered to rats ~~and observing the~~through observation of amount of feeding, body weight and fat weight, ~~and so on after the~~administration of relaxin-3. ~~According to the present invention,~~This invention includes: a polypeptide having useful effects in stimulating feeding, increasing body weight, and fattening; a therapeutic agent containing ~~thesaid~~ polypeptide; a method of screening for a compound, a substance, or a salt thereof which activates or suppresses a receptor of ~~thesaid~~ polypeptide; a kit for ~~said~~ screening; and an agent ~~which comprises~~with a substance which inhibits expression of ~~thesaid~~ polypeptide, such as a ~~feeding-suppressing~~feeding-suppressing agent, a therapeutic agent for the treatment of obesity, and a therapeutic agent for the treatment of diabetes.

**In the Specification:**

*Please replace the paragraph on page 13 lines 10-17, with the following paragraph, marked-up to show changes made.*

~~Fig. 4~~Fig. 4A-B shows the evaluation (screening) for relaxin-3 antagonistic compounds using SALPR-SE302 cells. ~~Fig. 4A~~ Panel A is the case where SALPR-SE302 cells were used. ~~and Fig. 4B~~Panel B is the case where SE302 cells were used. In ~~the figures~~this figure, FK(-) shows the forskolin non-treatment group; FK(+), the 3  $\mu$ M forskolin treatment group; FK(+)&RLX-3, the forskolin and 3 nM relaxin-3 treatment group; and FK(+)&RLX-3&compound 1, the group treated with a combination of forskolin, relaxin-3, and compound 1.

*Please replace the paragraph on page 14 lines 13-25, with the following paragraph, marked-up to show changes made.*

~~Fig. 10~~Fig. 10A-B shows the change in the blood hormone level by a chronic intracerebroventricular administration of relaxin-3 to normal rats. ~~Fig. 10A~~ Panel A shows the effect on the blood leptin concentration. The white rectangular bar shows the vehicle administration group (control) and the black rectangular bar shows the relaxin-3 administration group. The vertical axis shows the mean and standard deviation of the blood leptin concentration (ng/ml) per animal in each group. ~~Fig. 10B~~Panel B shows the effect on the blood insulin concentration. The white rectangular bar shows the vehicle administration group (control) and the black rectangular bar shows the relaxin-3 administration group. The vertical axis shows the mean and standard deviation of the blood insulin concentration (ng/ml) per animal in each group.